Rhodium and its compounds as potential agents in cancer treatment

Glutathione binding to dirhodium tetraacetate: a spectroscopic, mass spectral and computational study of an anti-tumour compound

“…Dirhodium(II) carboxylates and their derivatives are an emerging class of anti-tumour compounds that are described as exhibiting greater potency than cisplatin in vitro [32][33][34][35][36][37][38] . However, significantly, with respect to possible cellular chemistry, rhodium(II) carboxylates bind strongly to sulfur containing compounds 32,33,35,37,[39][40][41] . Indeed, the propensity for these rhodium complexes to deplete intracellular thiols makes them especially useful as radiosensitizers 42,43 .…”

Synthesis, Characterization and Analysis of Leishmanicide Ability of the Compound [Ru(Cl)<sub>3</sub>(H<sub>2</sub>O)<sub>2</sub>(gly)]

“…In 1969, the antitumor activity of metallic complexes containing cisplatin was discovered (Katsaros and Anagnostopoulou 2002) [4] enabling the development of new antitumor drugs such as complexes involving organic metals and/or inorganic platinum, ruthenium and rhodium (PAULA et al 2005; Waxman and Anderson 2001) [5] [6]. Gallori and colleagues suggest that compounds containing ruthenium can bind to the DNA molecule, and that this interaction can alter the cell cycle, causing cell death through mechanisms such as apoptosis (Gallori et al 2000) [7].…”

Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity

“…These Ru compounds exhibit low general toxicity, which contrasts to the pharmacological properties of Pt drugs. Organometallic half-sandwich h  -arene (such as p-cymene, biphenyl) or h  -cyclopentadienyl complexes of Ru and Os are extensively investigated, however relatively few studies are focused on related Rh(II/III) compounds with antitumor activity [7][8][9]. The anticancer properties of RhCl 3 have been known for many decades [10].…”